Drawing for SANKYO

USPTO serial 75253714

SANKYO

Reviewed by CopyMark Law Group

Reg. 2231395Status 710
Filing date
Status date
Registration date
Mar 16, 1999
Examiner
CHICOSKI, JENNIFER D
Law office
POST REGISTRATION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with SANKYO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

PETER J TOREN

PETER J TOREN SIDLEY AUSTIN BROWN & WOOD LLP787 7TH AVENEW YORK, NY 10019-6018UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001[hormone-based preparations for application to domestic and/or agricultural plants for use as a growth regulator; excipients, namely, tablet coating polymer beads for use in manufacturing pharmaceutical preparations soluble in the gastric tract]SECTION 8 - CANCELLED—
002[beta-carotene for use as a colorant in the manufacture of pharmaceutical preparations]SECTION 8 - CANCELLED—
005[central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents,] diuretics, hypotensors,[prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives, antacids, hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis, corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, crohn's disease, and chronic active hepatitis; estrogen and progesterone used as combined oral contraceptives; urinary antiseptics, analgesics,anti-itching agents, cataplasms for the treatment of bruises, lumbago and stiff shoulder, pharmaceutical preparations used to treat hair disorders, vitamin preparations, food enriching agents for treating vitamin deficiencies, anti-coagulants, enzyme preparations for control of malabsorption and diarrhea,] [anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmosis, naturally occurring drugs for treating peptic ulcers, charred drugs for treating peptic ulcers, moxa for treating peptic ulcers, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidium in chickens, and dysentery in pigs, germination controllers and plant rearing agents, namely, herbicide], fungicides,[ insecticides, bactericides and rodenticides for domestic and/or agricultural use, antiseptics, drugs for arteriosclerosis, oncostatic drugs for the treatment of cancer, multienzyme digestants for in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, antiparkinsonism drugs, minor tranquilizers, and antianxiety agents]SECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 17, 2009CAEXCANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9—
Sep 19, 2007ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jul 8, 20058.PRREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED—
May 10, 2005PLGLASSIGNED TO PARALEGAL—
Mar 14, 20058.AFREGISTERED - SEC. 8 (6-YR) FILED—
Mar 14, 2005ES8RTEAS SECTION 8 RECEIVED—
Feb 26, 2003TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 16, 1999R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 22, 1998PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 20, 1998NPUBNOTICE OF PUBLICATION—
Oct 5, 1998CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 25, 1998DOCKASSIGNED TO EXAMINER—
Aug 14, 1998CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 11, 1998CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 27, 1998CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 29, 1997CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 17, 1997DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance